Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model

PORTU, AGUSTINA; POZZI, EMILIANO C. C.; MONTI HUGHES, ANDREA; TRIVILLIN, VERÓNICA A.; GARABALINO, MARCELA A.; SAINT MARTIN, GISELA; CUROTTO, PAULA; COLOMBO, LUCAS L.; MARSHALL, GUILLERMO; OLAIZ, NAHUEL; THORP, SILVIA I.; ITOIZ, MARÍA E.; NIGG, DAVID W.; SCHWINT, AMANDA E.

RADIATION AND ENVIRONMENTAL BIOPHYSICS

SPRINGER

Año: 2019 vol. 58 p. 455 - 467

0301-634X

Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.